Expert: Oral At-Home Pill May Change the Game for COVID-19 Treatment

Michael Frank, CEO of Revive Therapeutics, discussed the results of a phase 3 trial investigating bucillamine as an oral at-home pill for the treatment of COVID-19 symptoms.

Pharmacy Times interviewed Michael Frank, CEO of Revive Therapeutics, on a phase 3 trial investigating the use of bucillamine as an oral at-home pill for the treatment of COVID-19 symptoms.

During the discussion, Frank addressed why bucillamine was investigated as a potential treatment for COVID-19; whether bucillamine is already FDA-approved for other treatment targets; which COVID-19 symptoms bucillamine has shown the potential to treat; how bucillamine is unique as a treatment for COVID-19 symptoms; what the timeline for a potential FDA approval of bucillamine may be; whether the FDA has fast-tracked bucillamine’s expanded approval in a fashion similar to other COVID-19 treatments; and how bucillamine could change the landscape for the currently available COVID-19 treatments.